

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Healy John Stephen</u> _____ (Last) (First) (Middle) C/O TYRA BIOSCIENCES, INC. 2656 STATE STREET _____ (Street) CARLSBAD CA 92008 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/01/2022	3. Issuer Name and Ticker or Trading Symbol <u>Tyra Biosciences, Inc. [TYRA]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>General Counsel and Secretary</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (Right to Buy)	(1)	03/09/2021	Common Stock	51,948	2.25	D
Stock Option (Right to Buy)	(2)	06/23/2031	Common Stock	134,937	10.75	D
Stock Option (Right to Buy)	(3)	11/01/2031	Common Stock	83,626	24.15	D
Stock Option (Right to Buy)	(4)	11/01/2031	Common Stock	7,964	24.15	D
Stock Option (Right to Buy)	(4)	11/01/2031	Common Stock	7,964	24.15	D

Explanation of Responses:

- 1/48th of the shares subject to the option vest monthly following February 26, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
- 25% of the shares subject to the option shall vest on March 5, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
- 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
- The option vests based on achievement of a performance objective.

Remarks:

/s/ John Stephen Healy 03/03/2022
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.